Flavonoid and experimental senolytic fact sheet
Fisetin
Also known as senolytic flavonoid, dietary fisetin
Fisetin can affect senescent cells in laboratory and animal models. Human geroscience studies remain small or unfinished, so anti-aging claims are ahead of outcomes evidence.
Quick answer
Fisetin is not an FDA-approved senolytic or anti-aging drug. Animal studies and early human mechanistic research justify clinical trials, but there is no proof that fisetin extends human life, reverses frailty, or prevents age-related disease.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Fisetin?
Fisetin is a flavonoid found in small amounts in foods such as strawberries and apples.
In geroscience it is studied as a senolytic—a compound intended to preferentially remove some senescent cells—but cell type, exposure, and model strongly affect that claim.
Why are people interested in it?
A prominent mouse study reported reduced senescence markers, improved health measures, and longer lifespan.
Human trials now examine vascular function, frailty, and treatment-related physical decline, but a trial design or biomarker shift is not a clinical benefit.
Current regulatory status
Fisetin is being studied in human trials but has no FDA-approved drug use for senescence, frailty, cardiovascular aging, cancer recovery, or longevity. Supplement products are not FDA approved for effectiveness.
What is it approved for?
No FDA-approved use. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.
What is it being studied for?
Evidence snapshot
The most influential healthspan and lifespan findings are from mice and cell systems. Human work is early, mechanistic, small, or still recruiting and does not establish better function, fewer diseases, or longer life.
Potential benefits being researched
- Preclinical work supports a senolytic hypothesis and identified cell-type-specific effects.
- Early human research may clarify target engagement, but meaningful clinical outcomes remain unproven.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- A food constituent is not automatically safe at concentrated research exposure.
- Human adverse-event data are too limited to define uncommon, interaction, or long-term risks.
- Supplement identity, purity, and formulation may not match clinical-trial material.
What we still do not know
- Whether fisetin reliably clears clinically relevant senescent cells in people
- Whether biomarker effects improve function, disease risk, or survival
- Which tissues and populations could benefit or be harmed
- Long-term safety and interactions
Plain-English takeaway
Fisetin is one of the better-known experimental senolytics, but its reputation still rests mainly on preclinical work. Human longevity benefit has not been shown.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1Preclinical fisetin healthspan and lifespan study
Cell, tissue, and mouse evidence that motivated human senolytic research.
- 2ClinicalTrials.gov: AFFIRM-LITE
Small Phase 2 frailty trial record with no posted outcomes result.
- 3Early human fisetin vascular-aging study
Mechanistic human study that does not establish longevity or disease prevention.
- 4FDA: dietary supplements are not preapproved for effectiveness
FDA explanation of the regulatory distinction between approved drugs and marketed dietary supplements.